Claude Mythos only model to complete full cyber kill chain, experts say
Booz Allen's Cyber Weapon Index finds only Claude Mythos completed an autonomous full cyber kill chain; mainstream AI-driven attacks deemed imminent.
Booz Allen's first Cyber Weapon Index tested 18 US and Chinese AI models on autonomous offensive cyber capability, combining vulnerability research and kill-chain attainment scores. Anthropic's Claude Mythos topped the index at 80 and was the only model to autonomously complete a full cyber kill chain, achieving administrator access with stolen credentials in every attempt and full domain compromise even without credentials; Grok-4.5 (49), GPT-5.6 Sol (46), Muse Spark 1.1 (38), and Kimi K3 (38) followed. All nine frontier API models scored zero against real-world bugs versus near-ceiling scores on planted ones, and pairing Claude Sonnet with a well-built attack harness rivaled Mythos' performance. Booz Allen predicts most tested models will reach Mythos' weaponization level within six months, calls AI-enabled mainstream attacks imminent, and urges sector-specific critical-infrastructure resilience deadlines and US cyber 'overmatch'.
Bisonal Malware Used in Attacks Against Russia and South Korea
Unit 42 details a Bisonal malware variant, active since 2014, targeting Russian and South Korean defense organizations via PDF-disguised spearphishing emails.
In early May, Unit 42 discovered a campaign delivering a Bisonal malware variant against at least one Russian communications security and cryptography company and one unidentified organization in South Korea. The variant, in the wild since at least 2014, introduces a new C2 cipher and rewritten networking and persistence code, with only 14 samples collected to date. Attackers spoofed Russian state corporation Rostec in spearphishing emails carrying an executable disguised with a PDF icon; the dropper decrypts an RC4-encrypted DLL and establishes persistence via a registry Run key. Bisonal has been used since 2013 against government, military, and defense targets in South Korea, Russia, Japan, and India, alongside successors Bioazih and Dexbia.